Total Payments
$399.21
2023 Payments
$145.88
Companies
4
Transactions
11
Medicare Patients
5,859
Medicare Billing
$280,771
Payment Breakdown by Category
Food & Beverage$269.21 (67.4%)
Consulting$130.00 (32.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $269.21 | 10 | 67.4% |
| Consulting Fee | $130.00 | 1 | 32.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $190.81 | 5 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $130.00 | 1 | $0 (2020) |
| Genentech USA, Inc. | $42.24 | 3 | $0 (2019) |
| SANOFI PASTEUR INC. | $36.16 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $145.88 | 2 | GlaxoSmithKline, LLC. ($125.00) |
| 2022 | $41.22 | 2 | GlaxoSmithKline, LLC. ($41.22) |
| 2020 | $169.87 | 4 | Teva Pharmaceuticals USA, Inc. ($130.00) |
| 2019 | $30.13 | 2 | Genentech USA, Inc. ($30.13) |
| 2018 | $12.11 | 1 | Genentech USA, Inc. ($12.11) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/25/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: RESPIRATORY | ||||||
| 06/05/2023 | SANOFI PASTEUR INC. | MENQUADFI (Biological), VAXELIS | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Vaccines | ||||||
| 07/18/2022 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), BEXSERO, PEDIARIX | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: VACCINES | ||||||
| 03/07/2022 | GlaxoSmithKline, LLC. | BEXSERO (Biological), SHINGRIX | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: VACCINES | ||||||
| 12/08/2020 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: VACCINES | ||||||
| 11/23/2020 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $11.86 | General |
| Category: VACCINES | ||||||
| 11/10/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Consulting Fee | Cash or cash equivalent | $130.00 | General |
| Category: Central Nervous System | ||||||
| 02/10/2020 | SANOFI PASTEUR INC. | FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE (Biological), FLUZONE QUADRIVALENT, FLUZONE HIGH-DOSE | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Vaccines | ||||||
| 08/21/2019 | Genentech USA, Inc. | OCREVUS (Biological) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Immunology | ||||||
| 06/19/2019 | Genentech USA, Inc. | OCREVUS (Biological) | Food and Beverage | In-kind items and services | $12.63 | General |
| Category: Immunology | ||||||
| 05/30/2018 | Genentech USA, Inc. | OCREVUS (Biological) | Food and Beverage | In-kind items and services | $12.11 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 1,227 | 1,230 | $128,656 | $82,680 |
| 2022 | 9 | 1,923 | 1,931 | $146,840 | $90,031 |
| 2021 | 11 | 2,274 | 2,274 | $131,271 | $88,343 |
| 2020 | 6 | 435 | 435 | $26,846 | $19,717 |
Total Patients
5,859
Total Services
5,870
Medicare Billing
$280,771
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 212 | 213 | $37,154 | $27,366 | 73.7% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 318 | 318 | $43,591 | $22,874 | 52.5% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 40 | 40 | $21,220 | $11,282 | 53.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 334 | 334 | $13,360 | $9,562 | 71.6% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 212 | 213 | $8,520 | $8,130 | 95.4% |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 44 | 45 | $1,800 | $1,718 | 95.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 42 | 42 | $1,680 | $1,202 | 71.6% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 25 | 25 | $1,332 | $545.88 | 41.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 366 | 366 | $50,171 | $25,086 | 50.0% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 503 | 503 | $20,120 | $18,188 | 90.4% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 48 | 48 | $32,103 | $13,361 | 41.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 408 | 409 | $16,360 | $11,155 | 68.2% |
| 0004A | Adm sarscov2 30mcg/0.3ml bst | Office | 2022 | 281 | 281 | $11,240 | $10,248 | 91.2% |
| 0054A | Adm sarscv2 30mcg trs-sucr b | Office | 2022 | 187 | 193 | $7,720 | $7,014 | 90.9% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2022 | 16 | 16 | $3,930 | $2,114 | 53.8% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 69 | 70 | $2,800 | $1,917 | 68.5% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 45 | 45 | $2,396 | $947.93 | 39.6% |
| 0003A | Fee covid-19 vac 1 booster | Office | 2021 | 1,030 | 1,030 | $41,200 | $38,293 | 92.9% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 275 | 275 | $35,500 | $17,947 | 50.6% |
| 0004A | Fee covid-19 vac 1 res | Office | 2021 | 241 | 241 | $9,640 | $8,968 | 93.0% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2021 | 53 | 53 | $11,839 | $6,650 | 56.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 378 | 378 | $15,120 | $5,984 | 39.6% |
| 90670 | Pneumococcal vaccine for injection into muscle | Office | 2021 | 13 | 13 | $5,283 | $3,138 | 59.4% |
| 90686 | Vaccine for influenza for administration into muscle, 0.5 ml dosage, quadrivalent, preservation free | Office | 2021 | 110 | 110 | $5,808 | $2,258 | 38.9% |
| 0002A | Adm sarscov2 30mcg/0.3ml 2nd | Office | 2021 | 58 | 58 | $2,320 | $2,158 | 93.0% |
About Dr. Michael Parker, DO
Dr. Michael Parker, DO is a Occupational Medicine healthcare provider based in Batesville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1700933165.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Parker, DO has received a total of $399.21 in payments from pharmaceutical and medical device companies, with $145.88 received in 2023. These payments were reported across 11 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($269.21).
As a Medicare-enrolled provider, Parker has provided services to 5,859 Medicare beneficiaries, totaling 5,870 services with total Medicare billing of $280,771. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Occupational Medicine
- Other Specialties Preventive Medicine/Occupational Environmental Medicine
- Location Batesville, IN
- Active Since 01/05/2007
- Last Updated 04/01/2024
- Taxonomy Code 2083X0100X
- Entity Type Individual
- NPI Number 1700933165
Products in Payments
- AJOVY (Biological) $130.00
- AREXVY (Drug) $125.00
- SHINGRIX (Biological) $45.21
- OCREVUS (Biological) $42.24
- MENQUADFI (Biological) $20.88
- BEXSERO (Biological) $20.60
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE (Biological) $15.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.